NK Cells and Immune ''Memory'' Joseph C
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
IFM Innate Immunity Infographic
UNDERSTANDING INNATE IMMUNITY INTRODUCTION The immune system is comprised of two arms that work together to protect the body – the innate and adaptive immune systems. INNATE ADAPTIVE γδ T Cell Dendritic B Cell Cell Macrophage Antibodies Natural Killer Lymphocites Neutrophil T Cell CD4+ CD8+ T Cell T Cell TIME 6 hours 12 hours 1 week INNATE IMMUNITY ADAPTIVE IMMUNITY Innate immunity is the body’s first The adaptive, or acquired, immune line of immunological response system is activated when the innate and reacts quickly to anything that immune system is not able to fully should not be present. address a threat, but responses are slow, taking up to a week to fully respond. Pathogen evades the innate Dendritic immune system T Cell Cell Through antigen Pathogen presentation, the dendritic cell informs T cells of the pathogen, which informs Macrophage B cells B Cell B cells create antibodies against the pathogen Macrophages engulf and destroy Antibodies label invading pathogens pathogens for destruction Scientists estimate innate immunity comprises approximately: The adaptive immune system develops of the immune memory of pathogen exposures, so that 80% system B and T cells can respond quickly to eliminate repeat invaders. IMMUNE SYSTEM AND DISEASE If the immune system consistently under-responds or over-responds, serious diseases can result. CANCER INFLAMMATION Innate system is TOO ACTIVE Innate system NOT ACTIVE ENOUGH Cancers grow and spread when tumor Certain diseases trigger the innate cells evade detection by the immune immune system to unnecessarily system. The innate immune system is respond and cause excessive inflammation. responsible for detecting cancer cells and This type of chronic inflammation is signaling to the adaptive immune system associated with autoimmune and for the destruction of the cancer cells. -
Discussion of Natural Killer Cells and Innate Immunity
Discussion of natural killer cells and innate immunity Theresa L. Whiteside, Ph.D. University of Pittsburgh Cancer Institute Pittsburgh, PA 15213 Myths in tumor immunology • Cancer cells are ignored by the immune system • Immune responses are directed only against “unique” antigens expressed on tumor cells • Tumor-specific T cells alone are sufficient for tumor regression • Tumor are passive targets for anti-tumor responses Tumor/Immune Cells Interactions Tumor cell death C G DC M TUMOR NK Th B Tc Ab Ag Ag/Ab complex NK cells as anti-tumor effectors • LGL, no TCR, express FcγRIII, other activating receptors and KIRs • Spare normal cells but kill a broad range of tumor cells ex vivo by at least two different mechanisms • Produce a number of cytokines (IFN-γ, TNF-α) • Constitutively express IL-2Rβγ and rapidly respond to IL-2 and also to IL-15 and IFNα/β • Regulated by a balance of inhibitory receptors specific for MHC class I antigens and activating signals • NK-DC interactions at sites of inflammation Heterogeneity of human NK cells • Every NK cell expresses at least one KIR that recognizes a self MHC class I molecule • Two functionally distinct subsets: 1) 90% CD56dimCD16bright , highly cytotoxic, abundant KIR expression, few cytokines 2) 10% CD56brightCD16dim/neg, produce cytokines, poorly cytotoxic, low KIR expression Expression of activating and inhibitory receptors on NK cells Interaction with CD56 Interaction with MHC ligands non-MHC ligands KIR CD16 CD2 CD94/NKG2A/B β2 NKp46, 44, 30 CD94/NKG2C/E NK Cell 2B4 NKG2D Lair1 LIR/ILT A -
One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma
One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy Laurie Besson, Emily Charrier, Lionel Karlin, Omran Allatif, Antoine Marçais, Paul Rouzaire, Lucie Belmont, Michel Attal, Christine Lombard, Gilles Salles, et al. To cite this version: Laurie Besson, Emily Charrier, Lionel Karlin, Omran Allatif, Antoine Marçais, et al.. One- Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy. Frontiers in Immunology, Frontiers, 2018, 9, pp.704. 10.3389/fimmu.2018.00704. hal-01833354 HAL Id: hal-01833354 https://hal.archives-ouvertes.fr/hal-01833354 Submitted on 22 Oct 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License ORIGINAL RESEARCH published: 13 April 2018 doi: 10.3389/fimmu.2018.00704 One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy Laurie Besson1,2,3,4,5,6†, Emily Charrier1,2,3,4,5,6†, -
COVID-19 Natural Immunity
COVID-19 natural immunity Scientific brief 10 May 2021 Key Messages: • Within 4 weeks following infection, 90-99% of individuals infected with the SARS-CoV-2 virus develop detectable neutralizing antibodies. • The strength and duration of the immune responses to SARS-CoV-2 are not completely understood and currently available data suggests that it varies by age and the severity of symptoms. Available scientific data suggests that in most people immune responses remain robust and protective against reinfection for at least 6-8 months after infection (the longest follow up with strong scientific evidence is currently approximately 8 months). • Some variant SARS-CoV-2 viruses with key changes in the spike protein have a reduced susceptibility to neutralization by antibodies in the blood. While neutralizing antibodies mainly target the spike protein, cellular immunity elicited by natural infection also target other viral proteins, which tend to be more conserved across variants than the spike protein. The ability of emerging virus variants (variants of interest and variants of concern) to evade immune responses is under investigation by researchers around the world. • There are many available serologic assays that measure the antibody response to SARS-CoV-2 infection, but at the present time, the correlates of protection are not well understood. Objective of the scientific brief This scientific brief replaces the WHO Scientific Brief entitled “’Immunity passports’ in the context of COVID-19”, published 24 April 2020.1 This update is focused on what is currently understood about SARS-CoV-2 immunity from natural infection. More information about considerations on vaccine certificates or “passports”will be covered in an update of WHO interim guidance, as requested by the COVID-19 emergency committee.2 Methods A rapid review on the subject was undertaken and scientific journals were regularly screened for articles on COVID-19 immunity to ensure to include all large and robust studies available in the literature at the time of writing. -
Role for NK Cells Inflammatory Response Reveals a Critical A
A Fatal Cytokine-Induced Systemic Inflammatory Response Reveals a Critical Role for NK Cells This information is current as William E. Carson, Haixin Yu, Julie Dierksheide, Klaus of September 28, 2021. Pfeffer, Page Bouchard, Reed Clark, Joan Durbin, Albert S. Baldwin, Jacques Peschon, Philip R. Johnson, George Ku, Heinz Baumann and Michael A. Caligiuri J Immunol 1999; 162:4943-4951; ; http://www.jimmunol.org/content/162/8/4943 Downloaded from References This article cites 61 articles, 37 of which you can access for free at: http://www.jimmunol.org/content/162/8/4943.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1999 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. A Fatal Cytokine-Induced Systemic Inflammatory Response Reveals a Critical Role for NK Cells1 William E. Carson,2*† Haixin Yu,† Julie Dierksheide,‡ Klaus Pfeffer,§ Page Bouchard,¶ Reed Clark,| Joan Durbin,| Albert S. -
High Mtor Activity Is a Hallmark of Reactive Natural Killer Cells And
RESEARCH ARTICLE High mTOR activity is a hallmark of reactive natural killer cells and amplifies early signaling through activating receptors Antoine Marc¸ais1,2,3,4,5*, Marie Marotel1,2,3,4,5, Sophie Degouve1,2,3,4,5, Alice Koenig1,2,3,4,5, Se´ bastien Fauteux-Daniel1,2,3,4,5, Annabelle Drouillard1,2,3,4,5, Heinrich Schlums6, Se´ bastien Viel1,2,3,4,5,7, Laurie Besson1,2,3,4,5, Omran Allatif1,2,3,4,5, Mathieu Ble´ ry8, Eric Vivier9,10, Yenan Bryceson6,11, Olivier Thaunat1,2,3,4,5, Thierry Walzer1,2,3,4,5* 1CIRI, Centre International de Recherche en Infectiologie - International Center for Infectiology Research, Lyon, France; 2Inserm, U1111, Lyon, France; 3Ecole Normale Supe´rieure de Lyon, Lyon, France; 4Universite´ Lyon 1, Lyon, France; 5CNRS, UMR5308, Lyon, France; 6Centre for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden; 7Laboratoire d’Immunologie, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Lyon, France; 8Innate-Pharma, Marseille, France; 9Aix-Marseille Universite´, CNRS, INSERM, CIML, Marseille, France; 10APHM, Hoˆpital de la Timone, Service d’Immunologie, Marseille, France; 11Broegelmann Research Laboratory, The Gades Institute, University of Bergen, Bergen, Norway Abstract NK cell education is the process through which chronic engagement of inhibitory NK *For correspondence: cell receptors by self MHC-I molecules preserves cellular responsiveness. The molecular [email protected] (AM); mechanisms responsible for NK cell education remain unclear. Here, we show that mouse NK cell [email protected] (TW) education is associated with a higher basal activity of the mTOR/Akt pathway, commensurate to Competing interest: See the number of educating receptors. -
Immunity ≠ Immunological Memory
Immunity ≠ Immunological Memory Rolf Zinkernagel University of Zurich IMI Stakeholder Forum - 13 May 2013 - Brussels • Protective vaccines imitate co-evolution of infectious agents and hosts. • We cannot do better than evolution by using the same tools, only when introducing ‘new’ tools (antibiotics, antivirals, autoantibodies, behavioural changes) • Vaccines against solid tumours (carcinomas, sarcomas) and chronic persistent infections are theoretically not impossible but practically highly unlikely! Vaccines Not successful available Polio 1, 2, 3 TB bact. toxins Leprosy measles HIV Haem. infl. malaria (cholera) Neutr. / effector T cells opsonising antibodies antibodies igG (IgA) IMMUNITY • "innate resistance" > 95 % • Ab in eggs • protective memory via Ab (vaccines) • TB: no vaccine • autoimmunity > 30 y, female > male 5 : 1 • tumors > 30 years • Is what we measure biologically important ? (e.g. acad. memory: earlier + greater) CTL ELISA nAb Immunity Immunology Protection • ‚Memory‘ • Small pox • quicker - higher • Poliomeningitis • Measles • HIV, malaria - • Tuberculosis ± Antibody Memory after immunization with VSV a) neutralizing antibodies b) ELISA 12 12 ) 10 ) 10 2 3 8 8 40 log 10 log 6 - - 6 NP binding NP - 4 IND neutralizing 4 - IgG ( IgG ( 2 VSV 2 VSV 0 0 0 20 100 200 300 0 20 100 200 300 days after immunization days after immunization Why immunological Memory ? Protection (immunity) counts ! • Earlier + better • If first infection survived no need for memory • If first infection kills no need for memory • All vaccines that -
Innate Immunity and Inflammation
ISBTc ‐ Primer on Tumor Immunology and Biological Therapy of Cancer InnateInnate ImmunityImmunity andand InflammationInflammation WillemWillem Overwijk,Overwijk, Ph.D.Ph.D. MDMD AndersonAnderson CancerCancer CenterCenter CenterCenter forfor CancerCancer ImmunologyImmunology ResearchResearch Houston,Houston, TXTX www.allthingsbeautiful.com InnateInnate ImmunityImmunity andand InflammationInflammation • Definitions • Cells and Molecules • Innate Immunity and Inflammation in Cancer • Bad Inflammation • Good Inflammation • Therapeutic Implications InnateInnate ImmunityImmunity andand InflammationInflammation • Definitions • Cells and Molecules • Innate Immunity and Inflammation in Cancer • Bad Inflammation • Good Inflammation • Therapeutic Implications • Innate Immunity: Immunity that is naturally present and is not due to prior sensitization to an antigen; generally nonspecific. It is in contrast to acquired/adaptive immunity. Adapted from Merriam‐Webster Medical Dictionary • Innate Immunity: Immunity that is naturally present and is not due to prior sensitization to an antigen; generally nonspecific. It is in contrast to acquired/adaptive immunity. • Inflammation: a local response to tissue injury – Rubor (redness) – Calor (heat) – Dolor (pain) – Tumor (swelling) Adapted from Merriam‐Webster Medical Dictionary ““InnateInnate ImmunityImmunity”” andand ““InflammationInflammation”” areare vaguevague termsterms •• SpecificSpecific cellcell typestypes andand moleculesmolecules orchestrateorchestrate specificspecific typestypes ofof inflammationinflammation -
Natural Killer Cell: Repertoire Development, Education and Activation
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2016 Natural Killer Cell: Repertoire Development, Education and Activation Landtwing, Vanessa Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-136828 Dissertation Originally published at: Landtwing, Vanessa. Natural Killer Cell: Repertoire Development, Education and Activation. 2016, University of Zurich, Faculty of Science. Natural Killer Cell: Repertoire Development, Education and Activation Dissertation zur Erlangung der naturwissenschaftlichen Doktorwürde (Dr.sc.nat.) vorgelegt der Mathematisch-naturwissenschaftlichen Fakultät Der Universität Zürich von Vanessa Sonja Landtwing von Zug ZG Promotionskomitee Prof. Dr. Christian Münz (Vorsitz, Leitung der Dissertation) Prof. Dr. med. Markus Manz Prof. Dr. Werner Held Zürich, 2016 Table of Contents TABLE OF CONTENTS Abbreviations ................................................................................................................................. 1 Chapter One - General Summary .................................................................................. 3 1.1 Zusammenfassung ............................................................................................................................. 5 1.2 Summary ................................................................................................................................................ 7 Chapter Two - Introduction .......................................................................................... -
Understanding the Immune System: How It Works
Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute NIH Publication No. 03-5423 September 2003 www.niaid.nih.gov www.nci.nih.gov Contents 1 Introduction 2 Self and Nonself 3 The Structure of the Immune System 7 Immune Cells and Their Products 19 Mounting an Immune Response 24 Immunity: Natural and Acquired 28 Disorders of the Immune System 34 Immunology and Transplants 36 Immunity and Cancer 39 The Immune System and the Nervous System 40 Frontiers in Immunology 45 Summary 47 Glossary Introduction he immune system is a network of Tcells, tissues*, and organs that work together to defend the body against attacks by “foreign” invaders. These are primarily microbes (germs)—tiny, infection-causing Bacteria: organisms such as bacteria, viruses, streptococci parasites, and fungi. Because the human body provides an ideal environment for many microbes, they try to break in. It is the immune system’s job to keep them out or, failing that, to seek out and destroy them. Virus: When the immune system hits the wrong herpes virus target or is crippled, however, it can unleash a torrent of diseases, including allergy, arthritis, or AIDS. The immune system is amazingly complex. It can recognize and remember millions of Parasite: different enemies, and it can produce schistosome secretions and cells to match up with and wipe out each one of them. -
Cytolytic Activity Cells Acquire Functional Receptors and Human Embryonic Stem Cell-Derived NK
Human Embryonic Stem Cell-Derived NK Cells Acquire Functional Receptors and Cytolytic Activity This information is current as Petter S. Woll, Colin H. Martin, Jeffrey S. Miller and Dan S. of September 23, 2021. Kaufman J Immunol 2005; 175:5095-5103; ; doi: 10.4049/jimmunol.175.8.5095 http://www.jimmunol.org/content/175/8/5095 Downloaded from References This article cites 57 articles, 29 of which you can access for free at: http://www.jimmunol.org/content/175/8/5095.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 23, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Human Embryonic Stem Cell-Derived NK Cells Acquire Functional Receptors and Cytolytic Activity1 Petter S. Woll,* Colin H. Martin,* Jeffrey S. Miller,† and Dan S. Kaufman2* Human embryonic stem cells (hESCs) provide a unique resource to analyze early stages of human hematopoiesis. -
Leukocytosis and Natural Killer Cell Function Parallel Neurobehavioral Fatigue Induced by 64 Hours of Sleep Deprivation
Leukocytosis and natural killer cell function parallel neurobehavioral fatigue induced by 64 hours of sleep deprivation. D F Dinges, … , E Icaza, M T Orne J Clin Invest. 1994;93(5):1930-1939. https://doi.org/10.1172/JCI117184. Research Article The hypothesis that sleep deprivation depresses immune function was tested in 20 adults, selected on the basis of their normal blood chemistry, monitored in a laboratory for 7 d, and kept awake for 64 h. At 2200 h each day measurements were taken of total leukocytes (WBC), monocytes, granulocytes, lymphocytes, eosinophils, erythrocytes (RBC), B and T lymphocyte subsets, activated T cells, and natural killer (NK) subpopulations (CD56/CD8 dual-positive cells, CD16- positive cells, CD57-positive cells). Functional tests included NK cytotoxicity, lymphocyte stimulation with mitogens, and DNA analysis of cell cycle. Sleep loss was associated with leukocytosis and increased NK cell activity. At the maximum sleep deprivation, increases were observed in counts of WBC, granulocytes, monocytes, NK activity, and the proportion of lymphocytes in the S phase of the cell cycle. Changes in monocyte counts correlated with changes in other immune parameters. Counts of CD4, CD16, CD56, and CD57 lymphocytes declined after one night without sleep, whereas CD56 and CD57 counts increased after two nights. No changes were observed in other lymphocyte counts, in proliferative responses to mitogens, or in plasma levels of cortisol or adrenocorticotropin hormone. The physiologic leukocytosis and NK activity increases during deprivation were eliminated by recovery sleep in a manner parallel to neurobehavioral function, suggesting that the immune alterations may be associated with biological pressure for sleep.